Biomarkers for delirium--a review
- PMID: 22091570
- PMCID: PMC3694326
- DOI: 10.1111/j.1532-5415.2011.03702.x
Biomarkers for delirium--a review
Abstract
To improve delirium recognition and care, numerous serum biomarkers have been investigated as potential tools for risk stratification, diagnosis, monitoring, and prognostication of delirium. The literature was reviewed, and no evidence was found to support the clinical use of any delirium biomarker, although certain biomarkers such as S-100 beta and insulin-like growth factor-1 and inflammatory markers have shown some promising results that need to be evaluated in future studies with appropriate sample size, prospective designs, and in a more-generalizable population.
© 2011, Copyright the Authors Journal compilation © 2011, The American Geriatrics Society.
Conflict of interest statement
Figures
References
-
- Witlox J, Nurslings LS, de Jungle JF, et al. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: A meta-analysis. JAMA. 2010;304:443–451. - PubMed
-
- Trzepacz PT. Is there a final common neural pathway in delirium? Focus on acetylcholine and dopamine. Semin Clin Neuropsychiatry. 2000;5:132–148. - PubMed
-
- De Rooij SE, van Munster BC, Korevaar JC, et al. Cytokines and acute phase response in delirium. J Psychosom Res. 2007;62:521–525. - PubMed
-
- Adamis D, Lunn M, Martin FC, et al. Cytokines and IGF-I in delirious and non-delirious acutely ill older medical inpatients. Age Ageing. 2009;38:326–332. discussion 251. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
